SCY-247
Life-threatening Invasive Fungal Infections (IV)
Key Facts
About Scynexis
Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.
View full company profileAbout Scynexis
Scynexis is committed to protecting the world against dangerous and difficult-to-treat fungal pathogens, a mission driven by its innovative 'fungerp' platform. The company achieved a significant milestone with the FDA approval and subsequent partnership with GSK for BREXAFEMME® (ibrexafungerp) for vulvovaginal candidiasis. Its strategic focus now includes advancing its second-generation fungerp, SCY-247, through clinical development for serious invasive infections, addressing the critical global threat of antimicrobial resistance.
View full company profile